Refining endpoints in brain tumor clinical trials

被引：36
作者：
Meyers, Christina A. [1 ]
Rock, Edwin P. [2 ]
Fine, Howard A. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[2] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA
[3] NCI, Neurooncol Branch, Bethesda, MD 20892 USA
来源：
JOURNAL OF NEURO-ONCOLOGY | 2012年 / 108卷 / 02期
关键词：
Brain cancer; Clinical trials; Neurocognitive function; NEUROCOGNITIVE FUNCTION; COGNITIVE FUNCTION; PROGRESSION; RADIATION; CANCER; GLIOMA;
D O I：
10.1007/s11060-012-0813-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.
引用
收藏
页码：227 / 230
页数：4
相关论文
共 50 条
  • [21] Are better endpoints and better design of clinical trials needed?
    Fransen, J
    van Riel, PLCM
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (01): : 97 - 109
  • [22] Interpretation of clinical endpoints in trials of acute myeloid leukemia
    Medeiros, Bruno C.
    LEUKEMIA RESEARCH, 2018, 68 : 32 - 39
  • [23] Novel Procedures for Validating Surrogate Endpoints in Clinical Trials
    Cleophas, Ton J.
    Zwinderman, Aeilko H.
    Chaib, Amel H.
    CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (02): : 123 - 128
  • [24] Imaging endpoints for clinical trials in MacTel type 2
    Pauleikhoff, Daniel
    Pauleikhoff, Laurenz
    Chew, Emily Y.
    EYE, 2022, 36 (02) : 284 - 293
  • [25] Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease
    Elghanam, Yomna
    Purja, Sujata
    Kim, Eun Young
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 99 (02) : 693 - 703
  • [26] Endpoints in clinical trials: does evidence only originate from 'hard' or mortality endpoints?
    Asmar, Roland
    Hosseini, Hassan
    JOURNAL OF HYPERTENSION, 2009, 27 : S45 - S50
  • [27] Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
    Ellingson, Benjamin M.
    Bendszus, Martin
    Boxerman, Jerrold
    Barboriak, Daniel
    Erickson, Bradley J.
    Smits, Marion
    Nelson, Sarah J.
    Gerstner, Elizabeth
    Alexander, Brian
    Goldmacher, Gregory
    Wick, Wolfgang
    Vogelbaum, Michael
    Weller, Michael
    Galanis, Evanthia
    Kalpathy-Cramer, Jayashree
    Shankar, Lalitha
    Jacobs, Paula
    Pope, Whitney B.
    Yang, Dewen
    Chung, Caroline
    Knopp, Michael V.
    Cha, Soonme
    van den Bent, Martin J.
    Chang, Susan
    Al Yung, W. K.
    Cloughesy, Timothy F.
    Wen, Patrick Y.
    Gilbert, Mark R.
    NEURO-ONCOLOGY, 2015, 17 (09) : 1188 - 1198
  • [28] Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints
    He, Pei
    CONTEMPORARY CLINICAL TRIALS, 2014, 38 (02) : 333 - 337
  • [29] Estimating and testing treatment effects on two binary endpoints and association between endpoints in clinical trials
    Wang, WQ
    Woolson, RF
    Clarke, WR
    COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2005, 34 (03) : 751 - 769
  • [30] The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials
    Krum, Henry
    Hopper, Ingrid
    JACC-HEART FAILURE, 2015, 3 (08) : 615 - 617
12345